Antiangiogenic therapy and immune checkpoint blockade go hand in hand
Ann Transl Med
.
2017 Dec;5(24):497.
doi: 10.21037/atm.2017.10.12.
Authors
Luis Felipe Campesato
1
,
Taha Merghoub
1
Affiliation
1
Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, NY, USA.
PMID:
29299458
PMCID:
PMC5750272
DOI:
10.21037/atm.2017.10.12
No abstract available
Publication types
Editorial
Comment
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States